November 22, 2021
Daiichi Sankyo said on November 18 that the first patient has been dosed in a global PIII study for datopotamab deruxtecan (Dato-DXd), a TROP2 directed antibody drug conjugate (ADC), for the second-line treatment of certain breast cancer patients. The TROPION-Breast01...read more